The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Managing progression after BCMA-targeted therapy in R/R multiple myeloma
Carlos Fernandez de Larrea, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the challenges associated with relapse after BCMA-targeted therapy with CAR-Ts, antibody-drug conjugates (ADCs) or bispecific antibodies, highlighting the potential of targeting other antigens in patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
